ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Files An 8-K Entry into a Material Definitive Agreement

ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Files An 8-K Entry into a Material Definitive Agreement

Story continues below

Item 1.01. Entry into a Material Definitive Agreement.

On May25, 2017, Adaptimmune Therapeutics plc (the Company or
Adaptimmune) entered into an agreement for lease with MEPC Milton
Park No.1 Limited and MEPC Milton Park No.2 Limited (MEPC) for
the lease of a building of approximately 46,000 square feet at
Milton Park, Oxfordshire, U.K (the Premises). Following the
completion of landlords works, the Company will enter into a
lease with MEPC of the Premises, which will provide additional
laboratory and office space. The Lease has a 22-year term with
break options exercisable by the Company on the fifth anniversary
of the Lease commencement date and at approximately five yearly
intervals thereafter. The rent payable under the Lease will be
approximately $279,930 (218,580 translated at a rate of 1 GBP =
1.28068 USD) for the first five months and then approximately
$559,861 (437,161) per year thereafter subject to reviews at
approximately five yearly intervals.

Item 8.01 Other Events.

On May26, 2017, the Company issued a press release announcing an
oral presentation, as well as four trials in progress posters, at
the 2017 ASCO annual meeting in Chicago,Illinois on June2 through
June6, 2017. During an oral presentation scheduled for June5th,
Dr.Sandra P. DAngelo of the Memorial Sloan Kettering Cancer
Center will present a full update on Cohorts 1, 2, 3, and 4 from
Adaptimmunes ongoing study of NY-ESO SPEAR T-cells in patients
with synovial sarcoma. In the same press release, the Company
also announced that it will host a webinar / teleconference on
June6th from 8:009:00 AM EDT (1:002:00 PM BST) to discuss this
updated synovial sarcoma clinical data. Call in details and the
webinar link will be made available in the Investors section of
Adaptimmunes website ( and will also
be provided in a subsequent ASCO press release on June5th. The
text of the press release is attached as Exhibit99.1 and is
incorporated by reference herein.

The information contained in Item 8.01 of this Form8-K, including
the attached Exhibit99.1, shall not be deemed filed for purposes
of Section18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act), or incorporated by reference in any filing
made by the Company under the Securities Act of 1933, as amended,
or the Exchange Act, except as expressly set forth by the Company
by specific reference in such a filing.

Item 9.01 Financial Statements and

(d) Exhibits. The following exhibit is furnished as part of this
Report on Form8-K:




Press Release dated May26, 2017


Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase their affinity to cancer-specific peptides, including its lead target peptides, NY-ESO-1 and MAGE-A10, in order to target and then destroy cancer cells in patients. The Company’s TCR therapeutic candidates are able to target intracellular, as well as extracellular cancer antigens. The TCRs consist of approximately two associated protein chains: the alpha and beta chains. Each of the chains has approximately two regions: a variable region and a constant region.


ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) closed its last trading session 00.00 at 5.30 with 171,864 shares trading hands.

An ad to help with our costs